JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive: reported that the combination of ruxolitinib and nilotinib, a second-generation TKI that is more potent than imatinib in CML, resulted in the enhanced eradication of CML stem/progenitor cells, highlighting JAK2 as a novel therapeutic target in CML stem/progenitor cells.